AIMSBioscience Signs MOU with DTNCRO in Clinical Research Field

Strengthening Capabilities in New Drug Development and Commercialization Services Expected

Lim Dong-seok, CEO of AIMS Bioscience (left), and Park Chae-gyu, CEO of DT&CRO, are taking a commemorative photo after signing an MOU. Photo by Ildong Pharmaceutical

AIMS BioScience, a new drug development strategy consulting company under Ildong Pharmaceutical Group, announced on the 20th that it has signed a Memorandum of Understanding (MOU) with Dt&CRO, a full-service Contract Research Organization (CRO), to collaborate in the fields of new drug research and development and clinical trials.

AIMS is a new drug development consulting company founded in 2019 by CEO Dongseok Lim, a clinical pharmacology professor at Catholic University Medical School. It possesses professional capabilities and an organization that meet global standards in clinical development and pharmacology, actively conducting business with leading pharmaceutical companies, research institutions, and universities.

Dt&CRO is an integrated CRO specializing in domestic and international regulatory clinical trials and late-stage clinical trials in the pharmaceutical and medical device sectors. It has the capability to comprehensively perform services ranging from non-clinical trials to Phase 1-3 clinical trials, PMS (post-marketing surveillance), OS (observational studies), and PV (pharmacovigilance), offering a full package service.

According to the MOU, AIMS and Dt&CRO will join forces in areas including ▲early-stage new drug development strategy and optimization of clinical trial design ▲efficiency in clinical trial operations and data management ▲development of innovative models based on DCT (decentralized clinical trials) ▲response to global clinical trial regulations and establishment of new drug approval strategies.

The two companies plan to provide consulting and services that support R&D business activities and smooth market entry for domestic and international pharmaceutical and bio companies by managing full-cycle projects from non-clinical stages to commercialization and addressing challenges that may arise during the new drug development process.

Additionally, beyond operating numerous ongoing Phase 1 clinical trial projects and bridging trial projects for global pharmaceutical companies in Korea, they will enhance government relations work such as responding to and consulting with regulatory bodies including the Ministry of Food and Drug Safety to provide differentiated services.

CEO Dongseok Lim of AIMS stated, "Through cooperation with Dt&CRO, we expect to further enhance our business capabilities in new drug development consulting and establish ourselves as a partner that contributes to improving the R&D competitiveness of domestic and international pharmaceutical and bio companies, including our clients, as well as to achieving commercialization results."

CEO Chaekyu Park of Dt&CRO said, "In addition to our own capabilities in clinical operations and management, we can provide systematic services linked with affiliated companies related to clinical analysis and software solutions within our parent company, Dt&C Bio Group. We will do our best to create an efficient new drug R&D ecosystem based on expertise together with AIMS."

This content was produced with the assistance of AI translation services.